Igor Puzanov, MD, Oncology, Buffalo, NY, Roswell Park Comprehensive Cancer Center

IgorPuzanovMD

Oncology Buffalo, NY

Genitourinary Oncology, Hematologic Oncology, Melanoma

Senior Vice President, Clinical Investigation; Judith and Stanford Lipsey Chair in Clinical Studies; Professor of Oncology and Medicine; Director, Center for Early Phase Clinical Trials; Chief of Early Phase Clinical Trials and Melanoma; Co-Leader, CCSG Experimental Therapeutics Program

Dr. Puzanov is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Puzanov's full profile

Already have an account?

Summary

  • Dr. Igor Puzanov is an oncologist in Buffalo, NY and is affiliated with Roswell Park Comprehensive Cancer Center. He received his medical degree from Charles University in Prague Faculty of Medicine and has been in practice 26 years. He also speaks multiple languages, including Czech, Russian, and Croatian. He specializes in genitourinary oncology, hematologic oncology, and melanoma and is experienced in amyloidosis, hematologic oncology, renal cell carcinoma, prostate cancer, and melanoma.

Education & Training

  • Vanderbilt University
    Vanderbilt UniversityMSCI, Clinical Investigation, 2004 - 2007
  • Vanderbilt University
    Vanderbilt UniversityFellowship, Hematology/Oncology, 2002 - 2005
  • University of Texas Southwestern Medical School
    University of Texas Southwestern Medical SchoolResidency, Internal Medicine, 1998 - 2001
  • Charles University in Prague Faculty of Medicine
    Charles University in Prague Faculty of MedicineClass of 1991

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2016 - 2022
  • TN State Medical License
    TN State Medical License 2002 - 2017
  • TX State Medical License
    TX State Medical License 2001 - 2005
  • OK State Medical License
    OK State Medical License 2000 - 2002
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Top Doctor Award Top Doctor Magazine, 2020-2021
  • Bridge 2018 Award for Lifelong Contributions to Melanoma Research Melanoma Foundation Onlus, 2018
  • Americas Top Oncologist Award Consumers Research Council of America, 2007
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: A Cytokine Working Group (CWG) study  
    Dandamudi UB, Ghebremichael M, Sosman JA, Clark JI, McDermott DF, Atkins MB, Dutcher JP, Urba WJ, Regan MM, Puzanov I, Crocenzi TS, Curti BD, Vaishampayan UN, Crosby N..., J Immunother, 11/1/2013
  • Future perspectives in melanoma research Meeting report from the "Melanoma Bridge Napoli, December 2nd-4th 2012"  
    Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J..., Journal of Translational Medicine, 6/1/2013
  • Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases  
    Puzanov I, Wolchok JD, Ascierto PA, Hamid O, Margolin K, Expert Rev. Dermatol, 1/1/2013
  • Join now to see all

Authored Content

  • Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020
  • Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020

Press Mentions

  • COVID-19 and Cancer: A Comprehensive Review
    COVID-19 and Cancer: A Comprehensive ReviewMay 8th, 2020
  • Does the Common Cold Virus Kill Bladder Cancer?
    Does the Common Cold Virus Kill Bladder Cancer?July 24th, 2019
  • Checkpoint Inhibitors May Be Retried After Immune Adverse Event, with Close Monitoring
    Checkpoint Inhibitors May Be Retried After Immune Adverse Event, with Close MonitoringJune 13th, 2019
  • Join now to see all

Grant Support

  • P30 Administrative supplement to support participation and leadership of RPCI in NCI ETCTN trialsNIH/NCI Early Therapeutics Clinical Trials Network (ETCTN)2016–2024
  • Roswell Park Comprehensive Cancer Center’s Center Support Grant (CCSG)NIH2014–2024
  • Genetic and phenotypic biomarkers to predict immune-related adverse events.UT Southwestern Medical Center/ACS2018–2021
  • RPCI CCSG/Early Phase Clinical Research SupportNIH/NCI2018–2019
  • Buffalo Clinical and Translational Research CenterNIH/SUNYat Buffalo/NCATS2015–2019
  • Development of novel immuno-PET techniques for in vivo study of anti-PDL1 antibody therapiesVICC2015
  • (IND 102, 133) Inhibition of Aurora Kinase A as Treatment for MelanomaFDA2009–2013
  • Molecular Based Targeted Therapy of MelanomaV Foundation2006–2009
  • The integrated laboratory and clinical assessment of new anticancer agents in early stages of human testingNIH/NCI2003–2009
  • PHI Study Of Daily X 5 Intravenous SJG-136National Center For Research Resources2006–2008
  • Task Order 1 to the Phase I Dose Escalation Study of Daily X 5 Intravenous SJG-136 in Patients with Advanced Solid TumorsTRI CTEP2005–2008
  • Research Career Development Program, (salary, MSCI tuition, laboratory research support)NIH K122004–2005

Committees

  • Member, SITC CTCAE Taskforce 2020 - Present
  • Member, SITC, Non-Melanoma Skin Cancer Immunotherapy Guideline (CIG) Expert Panel 2020 - Present
  • Member, SITC Immune Checkpoint Inhibitor and Cytokine‐related Adverse Event Subcommittee 2019 - Present
  • Member, ORIEN Scientific Retreat Planning Task Force 2019 - Present
  • Member, SITC Biomarkers Committee/Microbiome Subcommittee 2018 - Present
  • Member, NCCN Guidelines Panel Scientific Committee, Non-Melanoma Skin Cancer Panel (RPCCC) 2017 - Present
  • Member, I-O Policy Working Group Effort on Serious but Rare Adverse Events, Planning Group (organized by Immuno-Oncology Policy Working Group) 2017 - Present
  • Member, State University of New York at Buffalo CFAR Investigators (CNS Reservoirs Group) 2017 - Present
  • Member, Key Faculty Member, Drug Development Core Leadership Group, Clinical and Translational Science Award (CTSA), State University of New York at Buffalo 2017 - Present
  • Member, Society for Immunotherapy of Cancer, Membership Committee 2015 - Present
  • Member, Association of Community Cancer Centers (ACCC); Institute for Clinical Immuno-Oncology (ICLIO), faculty 2015 - Present
  • Member, Amgen, Steering Committee for a Phase Ib clinical trial of TVEC+pembrolizumab in patients with melanoma 2014 - Present
  • Member, International Consortium for Cell Therapy and Immunotherapy (EU) 2011 - Present
  • Member, NCI/EORTC/UK International Rare Cancer Initiative-ocular Melanoma Group 2011 - Present
  • Member, Masaryk Cancer Center, Masaryk University Brno, Czech Republic International Advisory Board, Phase I Drug Development 2011 - Present
  • Member, Melanoma Research Foundation Breakthrough Consortium Immunology Subcommittee/Angiogenesis Subcommittee 2010 - Present
  • Member, ECOG GU Core Committee 2010 - Present
  • Member, Bioanalytics, Metabolomics, and Pharmacokinetics Shared Resources Advisory Committee (RPCCC) 2016 - 2020
  • Member, Scientific Review Committee (RPCCC) 2016 - 2020
  • Member, Roche, Steering Committee for a Phase II clinical trial of vemurafenib in melanoma patients carrying nonV600E mutations 2011 - 2015
  • Member, Roche, Steering Committee for a Phase II clinical trial of vemurafenib in tumors carrying V600 mutations 2011 - 2015
  • Member, GlaxoSmithKline, Cutaneous Events Committee, RAF Inhibitors 2011 - 2014
  • Member, ACORDA Therapeutics, Inc. Data Safety and Monitoring Board, Phase I Study of GGF2 2011 - 2012
  • Member, Therapeutic Task Force and Translational Research Committee (Vanderbilt) 2010 - 2016
  • Member, Angiogenesis Task Force, Cardiotoxicity Group, NCI/CTEP 2010 - 2014
  • Member, Data Safety and Monitoring Committee (Vanderbilt) 2009 - 2016

Professional Memberships

Other Languages

  • Czech, Russian, Croatian

Hospital Affiliations